More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Prolonged exposure to silica dust, a common mineral found in materials like kitchen countertops, can lead to silicosis, a ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes ...

The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.